{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,8,27]],"date-time":"2026-08-27T16:48:23Z","timestamp":1787849303244,"version":"build-2784847793"},"reference-count":40,"publisher":"Wiley","issue":"2","license":[{"start":{"date-parts":[[2017,10,12]],"date-time":"2017-10-12T00:00:00Z","timestamp":1507766400000},"content-version":"vor","delay-in-days":0,"URL":"http:\/\/onlinelibrary.wiley.com\/termsAndConditions#vor"}],"content-domain":{"domain":[],"crossmark-restriction":false},"short-container-title":["Acad Dermatol Venereol"],"published-print":{"date-parts":[[2018,2]]},"abstract":"<jats:title>Abstract<\/jats:title><jats:sec><jats:title>Background<\/jats:title><jats:p>Apremilast is a novel oral phosphodiesterase\u20104 inhibitor approved for psoriasis treatment. Randomized trials have documented its efficacy and safety, but data on real\u2010world patients are scarce.<\/jats:p><\/jats:sec><jats:sec><jats:title>Objectives<\/jats:title><jats:p>We aim to characterize psoriasis patients treated with apremilast in a real\u2010world setting and calculate drug survival as an important measure of efficacy and compliance.<\/jats:p><\/jats:sec><jats:sec><jats:title>Methods<\/jats:title><jats:p>All patients with psoriasis who received apremilast between 1 April 2015 and 19 January 2017 were evaluated every 4\u00a0weeks, and we documented: age, weight, height, smoking status, family history of psoriasis, joint involvement, previous treatments, psoriasis area severity index (<jats:styled-content style=\"fixed-case\">PASI<\/jats:styled-content>) scores, and the onset and duration of adverse events (<jats:styled-content style=\"fixed-case\">AE<\/jats:styled-content>). Efficacy was analysed by <jats:styled-content style=\"fixed-case\">PASI<\/jats:styled-content>50, <jats:styled-content style=\"fixed-case\">PASI<\/jats:styled-content>75 and <jats:styled-content style=\"fixed-case\">PASI<\/jats:styled-content>90, reflecting the improvement of skin lesions compared to the <jats:styled-content style=\"fixed-case\">PASI<\/jats:styled-content>\u2010baseline. Kaplan\u2013Meier statistics were used for drug survival estimates.<\/jats:p><\/jats:sec><jats:sec><jats:title>Results<\/jats:title><jats:p>Forty\u2010eight patients were included. The median apremilast drug survival was 12.5\u00a0weeks (range 1\u201387). Three patients (6.3%) reached <jats:styled-content style=\"fixed-case\">PASI<\/jats:styled-content>90, nine (18.8%) PASI75 and eight patients (16.7%) <jats:styled-content style=\"fixed-case\">PASI<\/jats:styled-content>50. Patient weight inversely correlated with a <jats:styled-content style=\"fixed-case\">PASI<\/jats:styled-content>50 response (<jats:italic>P<\/jats:italic>\u00a0&lt;\u00a00.05, <jats:italic>n<\/jats:italic>\u00a0=\u00a037), and none of the obese patients (<jats:styled-content style=\"fixed-case\">BMI<\/jats:styled-content>\u00a0&gt;\u00a030.0, <jats:italic>n<\/jats:italic>\u00a0=\u00a06) reached <jats:styled-content style=\"fixed-case\">PASI<\/jats:styled-content>75, compared to 32% of the non\u2010obese patients (<jats:styled-content style=\"fixed-case\">BMI<\/jats:styled-content>\u00a0&lt;\u00a030.0, <jats:italic>n<\/jats:italic>\u00a0=\u00a031). Thirty\u2010one patients (64.6%) reported at least one <jats:styled-content style=\"fixed-case\">AE<\/jats:styled-content>, most frequently diarrhoea (<jats:italic>n<\/jats:italic>\u00a0=\u00a021, 43.8%), headache (<jats:italic>n<\/jats:italic>\u00a0=\u00a07, 14.6%) and joint pain (<jats:italic>n<\/jats:italic>\u00a0=\u00a05, 10.4%).<\/jats:p><\/jats:sec><jats:sec><jats:title>Conclusions<\/jats:title><jats:p>Despite differences between real\u2010world and trial patients, apremilast is safe and effective for the treatment of skin psoriasis in the daily practice. Up to 40% of patients will reach <jats:styled-content style=\"fixed-case\">PASI<\/jats:styled-content>50 or higher, but only few patients will reach <jats:styled-content style=\"fixed-case\">PASI<\/jats:styled-content>90. Bodyweight might affect drug efficacy.<\/jats:p><\/jats:sec>","DOI":"10.1111\/jdv.14598","type":"journal-article","created":{"date-parts":[[2017,9,19]],"date-time":"2017-09-19T09:16:43Z","timestamp":1505812603000},"page":"254-259","source":"Crossref","is-referenced-by-count":54,"title":["Apremilast in psoriasis \u2013 a prospective real\u2010world study"],"prefix":"10.1111","volume":"32","author":[{"given":"I.","family":"Vujic","sequence":"first","affiliation":[{"name":"Dermatology The Rudolfstiftung Hospital Vienna Austria"},{"name":"School of Medicine Sigmund Freud University Vienna Austria"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"R.","family":"Herman","sequence":"additional","affiliation":[{"name":"Dermatology The Rudolfstiftung Hospital Vienna Austria"},{"name":"School of Medicine Sigmund Freud University Vienna Austria"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"M.","family":"Sanlorenzo","sequence":"additional","affiliation":[{"name":"Department of Oncology University of Turin Italy"},{"name":"Institute of Cancer Research Department of Medicine I Comprehensive Cancer Center Medical University of Vienna Vienna Austria"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"C.","family":"Posch","sequence":"additional","affiliation":[{"name":"Dermatology The Rudolfstiftung Hospital Vienna Austria"},{"name":"School of Medicine Sigmund Freud University Vienna Austria"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"B.","family":"Monshi","sequence":"additional","affiliation":[{"name":"Dermatology The Rudolfstiftung Hospital Vienna Austria"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"K.","family":"Rappersberger","sequence":"additional","affiliation":[{"name":"Dermatology The Rudolfstiftung Hospital Vienna Austria"},{"name":"School of Medicine Sigmund Freud University Vienna Austria"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"L.","family":"Richter","sequence":"additional","affiliation":[{"name":"Dermatology The Rudolfstiftung Hospital Vienna Austria"}],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"311","published-online":{"date-parts":[[2017,10,12]]},"reference":[{"key":"e_1_2_5_2_1","doi-asserted-by":"publisher","DOI":"10.1046\/j.1087-0024.2003.09102.x"},{"key":"e_1_2_5_3_1","doi-asserted-by":"publisher","DOI":"10.1016\/j.jaad.2008.09.022"},{"key":"e_1_2_5_4_1","doi-asserted-by":"publisher","DOI":"10.1111\/j.1365-4632.2011.05154.x"},{"key":"e_1_2_5_5_1","doi-asserted-by":"publisher","DOI":"10.1186\/ar4317"},{"key":"e_1_2_5_6_1","doi-asserted-by":"publisher","DOI":"10.1155\/MI.2005.273"},{"key":"e_1_2_5_7_1","doi-asserted-by":"publisher","DOI":"10.1111\/j.1365-2133.2010.09992.x"},{"key":"e_1_2_5_8_1","doi-asserted-by":"publisher","DOI":"10.1016\/j.jdermsci.2009.01.003"},{"key":"e_1_2_5_9_1","doi-asserted-by":"publisher","DOI":"10.1146\/annurev-immunol-032713-120225"},{"key":"e_1_2_5_10_1","doi-asserted-by":"publisher","DOI":"10.1111\/j.1365-2133.2004.06070.x"},{"key":"e_1_2_5_11_1","doi-asserted-by":"crossref","first-page":"50","DOI":"10.1111\/ddg.12687","article-title":"Retrospective data collection of psoriasis treatment with fumaric acid esters in children and adolescents in Germany (KIDS FUTURE study)","volume":"14","author":"Reich K","year":"2016","journal-title":"J Dtsch Dermatol Ges J Ger Soc Dermatol JDDG"},{"key":"e_1_2_5_12_1","doi-asserted-by":"publisher","DOI":"10.1007\/s00403-012-1214-8"},{"key":"e_1_2_5_13_1","doi-asserted-by":"publisher","DOI":"10.1016\/j.jaad.2016.04.068"},{"key":"e_1_2_5_14_1","first-page":"309","article-title":"Etanercept, adalimumab, and ustekinumab in psoriasis: analysis of 209 treatment series in Austria","volume":"15","author":"Richter L","year":"2017","journal-title":"J Dtsch Dermatol Ges J Ger Soc Dermatol JDDG"},{"key":"e_1_2_5_15_1","doi-asserted-by":"publisher","DOI":"10.1111\/j.1468-3083.2009.03389.x"},{"key":"e_1_2_5_16_1","doi-asserted-by":"publisher","DOI":"10.1016\/S0140-6736(08)60726-6"},{"key":"e_1_2_5_17_1","unstructured":"European Medicines Agency. URLhttp:\/\/www.ema.europa.eu\/ema\/index.jsp?curl=pages\/home\/Home_Page.jsp. (last accessed: 30 April 2017)."},{"key":"e_1_2_5_18_1","doi-asserted-by":"publisher","DOI":"10.1038\/bjp.2008.307"},{"key":"e_1_2_5_19_1","doi-asserted-by":"publisher","DOI":"10.1155\/2015\/906349"},{"key":"e_1_2_5_20_1","doi-asserted-by":"publisher","DOI":"10.1111\/bjd.14164"},{"key":"e_1_2_5_21_1","first-page":"888","article-title":"Efficacy, tolerability, and pharmacodynamics of apremilast in recalcitrant plaque psoriasis: a phase II open\u2010label study","volume":"12","author":"Gottlieb AB","year":"2013","journal-title":"J Drugs Dermatol JDD"},{"key":"e_1_2_5_22_1","doi-asserted-by":"publisher","DOI":"10.1111\/j.1365-2133.2005.06688.x"},{"key":"e_1_2_5_23_1","doi-asserted-by":"publisher","DOI":"10.1016\/j.jaad.2015.03.049"},{"key":"e_1_2_5_24_1","doi-asserted-by":"publisher","DOI":"10.3899\/jrheum.140647"},{"key":"e_1_2_5_25_1","doi-asserted-by":"publisher","DOI":"10.1177\/1203475416676030"},{"key":"e_1_2_5_26_1","doi-asserted-by":"publisher","DOI":"10.1038\/jid.2015.208"},{"key":"e_1_2_5_27_1","doi-asserted-by":"publisher","DOI":"10.1111\/j.1365-2133.2010.09950.x"},{"key":"e_1_2_5_28_1","unstructured":"J Am Acad Dermatol Loss of efficacy of secukinumab for psoriasis at 24 to 32 weeks"},{"key":"e_1_2_5_29_1","doi-asserted-by":"publisher","DOI":"10.1111\/j.1365-2133.2011.10213.x"},{"key":"e_1_2_5_30_1","doi-asserted-by":"publisher","DOI":"10.1159\/000366499"},{"key":"e_1_2_5_31_1","doi-asserted-by":"publisher","DOI":"10.1111\/bjd.12648"},{"key":"e_1_2_5_32_1","unstructured":"CTCAE Files. URLhttps:\/\/evs.nci.nih.gov\/ftp1\/CTCAE\/About.html(last accessed 10 July 2017)."},{"key":"e_1_2_5_33_1","doi-asserted-by":"publisher","DOI":"10.1046\/j.1365-2125.2003.01953.x"},{"issue":"15","key":"e_1_2_5_34_1","first-page":"S405","article-title":"Differences between clinical trial efficacy and real\u2010world effectiveness","volume":"12","author":"Davidson MH","year":"2006","journal-title":"Am J Manag Care"},{"key":"e_1_2_5_35_1","first-page":"e34","article-title":"Drug survival studies in dermatology:principles, purposes, and pitfalls","volume":"135","author":"Reek JMPA","year":"2015","journal-title":"J Invest Dermatol"},{"key":"e_1_2_5_36_1","doi-asserted-by":"publisher","DOI":"10.1111\/bcp.12448"},{"key":"e_1_2_5_37_1","doi-asserted-by":"publisher","DOI":"10.1038\/nrclinonc.2014.104"},{"key":"e_1_2_5_38_1","doi-asserted-by":"publisher","DOI":"10.1158\/1078-0432.CCR-11-0997"},{"key":"e_1_2_5_39_1","doi-asserted-by":"publisher","DOI":"10.1038\/nutd.2011.9"},{"key":"e_1_2_5_40_1","doi-asserted-by":"publisher","DOI":"10.1038\/oby.2009.113"},{"key":"e_1_2_5_41_1","doi-asserted-by":"publisher","DOI":"10.2165\/11318100-000000000-00000"}],"container-title":["Journal of the European Academy of Dermatology and Venereology"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/api.wiley.com\/onlinelibrary\/tdm\/v1\/articles\/10.1111%2Fjdv.14598","content-type":"application\/pdf","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/onlinelibrary.wiley.com\/doi\/pdf\/10.1111\/jdv.14598","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2023,9,18]],"date-time":"2023-09-18T03:34:59Z","timestamp":1695008099000},"score":1,"resource":{"primary":{"URL":"https:\/\/onlinelibrary.wiley.com\/doi\/10.1111\/jdv.14598"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2017,10,12]]},"references-count":40,"journal-issue":{"issue":"2","published-print":{"date-parts":[[2018,2]]}},"alternative-id":["10.1111\/jdv.14598"],"URL":"https:\/\/doi.org\/10.1111\/jdv.14598","archive":["Portico"],"relation":{},"ISSN":["0926-9959","1468-3083"],"issn-type":[{"value":"0926-9959","type":"print"},{"value":"1468-3083","type":"electronic"}],"subject":[],"published":{"date-parts":[[2017,10,12]]}}}